The cholinergic amacrine cells of the rabbit retina may be labeled with 3H-choline, and the activity of the cholinergic population may be monitored by following the release of 3H-ACh. In magnesium-free medium, the glutamate analog NMDA caused massive ACh release, up to 50x the basal efflux. Magnesium blocked the NMDA-evoked release of ACh with an IC,, of 151 MM. The NMDA-evoked release of ACh was unchanged in glycine-free medium or in the presence of 500 @I glycine. However, the block of NMDA-evoked release by 7-chlorokynurenic acid (7-Cl-Kyn) was reversed by exogenous glycine. This suggests that the NMDA receptors mediating ACh release possess an allosteric glycine binding site, but under normal conditions, it is saturated by endogenous glycine.
Submaximal doses of NMDA were used to determine the potency of NMDA antagonists and their specificity was established with submaximal doses of other glutamate agonists. oL-2-amino-7-phosphonoheptanoate (DL-AP-7) was a competitive NMDA antagonist, with an IC,, of 33 PM, and (+)5-methyl-l 0,ll -dihydro-5H-dibenzo [a,d] Glutamate is gaining acceptance as the major excitatory neurotransmitter in the CNS, including the retina (Mayer and Westbrook, 1987; Massey, 1990) . Both physiological and biochemical evidence support the concept of multiple postsynaptic glutamate receptors (Foster and Fagg, 1984; Mayer and Westbrook, 1987) . One of these receptors is selectively activated by the glutamate analog NMDA. NMDA receptor activation leads to the gating of an ion channel permeable to monovalent cations and calcium (MacDermott et al., 1986) . There are several regulatory sites on this receptor complex in addition to the primary NMDA binding site (Reynolds and Miller, 1988; MacDonald et al., 1989; Monaghan et al., 1989; Thomson, 1989) . The analysis of these sites has provided specific pharmacological tools to investigate NMDA receptor function.
The first clue to the complexity of the NMDA receptor came from the study of magnesium, which blocks NMDA responses in a voltage-dependent manner (Nowak et al., 1984; Mayer and Westbrook, 1985) . This is considered the hallmark of the NMDA receptor, and it is not observed with other glutamate receptors. More recently, a strychnine-insensitive glycine binding site has been discovered that potentiates the action of NMDA (Johnson and Ascher, 1987) . This is a large effect: at a concentration of 1 PM or less, glycine potentiates the response to NMDA, or glutamate acting at NMDA receptors, by a factor of 10 or more. In fact, glycine may be an absolute requirement for NMDA receptor activation (Kleckner and Dingledine, 1988) . Kynurenic acid (Kyn) and the quinoxalinediones 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6,7-dinitroquinoxaline-2,3-dione (DNQX) are competitive antagonists at the glycine binding site of the NMDA receptor complex in several systems (Birch et al., 1988; Kessler et al., 1989) . Another analog, 7-chlorokynurenic acid (7-Cl-Kyn), is much more potent and has greater selectivity for the glycine site (Kemp et al., 1988) .
The physiological role of NMDA receptors has been examined in various parts ofthe CNS, and while they may play a significant role in such processes as long-term potentiation or kindling (Collingridge et al., 1983) there is general agreement that NMDA receptors do not mediate conventional, fast synaptic transmission (Crunelli et al., 1983) . However, this exclusion does not eliminate NMDA receptors from an important physiological role in the nervous system. NMDA receptors are the most sensitive to glutamate, and it has been suggested that their tonic activation by ambient glutamate enhances the excitability of neurons (Sah et al., 1989) . In some systems, there are dual postsynaptic glutamate receptors, and NMDA receptors mediate a slow component of the postsynaptic response (Dale and Roberts, 1985; Forsythe and Westbrook, 1988; Mittman and Taylor, 1988) .
In the vertebrate retina, NMDA receptors appear to be absent or rare on second-order neurons in the outer retina (Lasater and Dowling, 1982; Miller, 1983, 1985; Coleman et al., 1986; Massey and Miller, 1987) . In contrast, NMDA receptors are found on nearly all third-order neurons in the inner retina (Slaughter and Miller, 1983; Bloomfield and Dowling, 1985; Massey and Miller, 1988, 1990 ) but they contribute, at best, only a minor portion of the light-driven input (Coleman and Miller, 1989; Massey and Miller, 1990) . The cholinergic amacrine cells of the rabbit retina are a well-described subset of amacrine cells whose activity can be monitored by following ACh release (Masland and Livingstone, 1976; Massey and Redbum, 1982; Masland et al., 1984; Tauchi and Masland, 1984) . Perfusion with NMDA, in magnesium-free medium, causes massive ACh release from the rabbit retina. However, the lightevoked release of ACh seems to be mediated predominantly by kainate (KA) receptors (Cunningham and Neal, 1985; Linn et al., 1991) .
One goal of these experiments was to establish the dose and specificity of some recently developed NMDA antagonists in the mammalian retina. Second, we used these pharmacological tools to determine the contribution of NMDA receptors to the light-evoked release of ACh. Our results indicate that NMDA receptors mediating ACh release are regulated by magnesium and glycine, though the glycine site seems to be saturated under normal conditions. DL-2-Amino-7-phosphonoheptanoate (DL-AP-7) and (+)5-methyl-10,ll -dihydro-SH-dibenzo[a,d]cyclohepten-5, IO-imine hydrogen maleate (MK-80 1) are specific NMDA antagonists with different sites of action. Neither antagonist reduced the light-evoked release of ACh from the retina, so we were unable to demonstrate that NMDA receptors carry any part of the physiological input to cholinergic amacrine cells.
Materials and Methods
Preparation. The procedures followed in this paper are identical to those in the previous, companion paper (Linn et al., 199 l) , with minor modifications. Briefly, rabbits were deeply anesthetized with urethane (loading dose, 1.5 gm/kg, i.p.), and the orbit was infused with Xylocaine (2%). An in vivo retinal eyecup was prepared under dim red light (Massey and Redbum, 1982) , and cholinergic amacrine cells were labeled with 'H-choline ('H-Ch). After loading, the eyecup was perfused with Krebs' solution, at 37"C, until a steady baseline was obtained. Subsequently, 1 -min fractions were collected directly into vials and prepared for liquid scintillation counting. The retina was stimulated by ~-HZ flashing light for 4-min periods or perfused with test solutions as described in Results. Increments in the release of radioactivity were shown in the previous paper (Linn et al., 199 1) to indicate ACh release.
Solutions. All drugs were dissolved directly in choline-free Krebs' bicarbonate medium (Ames and Nesbett, 198 1) . Most experiments were conducted in magnesium-free medium to promote NMDA responses. MK-801 was generously provided by Merck, Sharp, and Dohme. All other drugs and reagents were obtained from commercial sources.
Results
Magnesium dependence When the retina was perfused with increasing doses of NMDA in the presence of normal physiological levels of magnesium (1.2 mM), there was no change in the release of ACh. Figure 1 demonstrates the complete absence of NMDA responses in the presence of magnesium, as previously reported by Cunningham and Neal (198 5) . At concentrations as high as 10 mM, no NMDA responses could be detected, even though the release of ACh in response to light and other glutamate agonists [e.g., a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)] was normal. NMDA was the only glutamate analog to exhibit this magnesium dependent block, KA, quisqualate (QQ), and AMPA responses were unchanged in the presence or absence of magnesium (Linn et al., 1991) .
To determine the concentration of magnesium required to block the response to NMDA, we applied a submaximal dose of NMDA (300 FM) in I-min pulses against a decreasing staircase of magnesium concentrations and measured the release of labeled ACh. We found that the IC,, for magnesium versus NMDA was 15 1 PM, the threshold dose was around 50 PM, and 0.7 mM magnesium caused a 95% reduction in the NMDAevoked release of ACh (see Fig. 1, inset) .
In magnesium-free medium, perfusion with NMDA caused massive ACh release much like other glutamate agonists (Linn et al., 1991) . Figure 2 shows the release of radioactivity in response to increasing doses of NMDA, reaching saturation at 25-30 times the basal efflux. The threshold dose for NMDA was 50 PM with an ED,, of 112 MM. Thus, NMDA was a moderately potent glutamate analog, approximately an order of magnitude less potent than KA or QQ (ED, , s, 12.4 and 10.3 PM, respectively) . From the dose-response curve, we chose to use a submaximal concentration of 300 PM NMDA in subsequent experiments, which were all performed in magnesium-free medium. Perfusate analysis identified the NMDA released radioactivity as 3H-ACh, and this indicates that the release originated from cholinergic amacrine cells (Linn et al., 199 1) .
Requirement for glycine Glycine potentiates NMDA responses in several systems (Johnson and Ascher, 1987; Thomson, 1989) and it may be required for NMDA receptor activation (Kleckner and Dingledine, 1988) .
The Krebs' solution used in these experiments contained 6 PM glycine (Ames and Nesbett, 1981 ) so we made a glycine-free version. However, the response to NMDA in glycine-free medium was unchanged, and the addition of up to 1 mM exogenous glycine failed to potentiate the release of ACh by NMDA. These results suggest that the high-affinity glycine binding site of the NMDA receptor complex may be saturated by endogenous glytine.
Alternatively, it could be argued that glycine had no effect because the NMDA receptors in this system are not associated with glycine binding sites. One way to investigate this possibility is to use antagonists recently demonstrated to act at this site, such as 'I-Cl-Kyn (Kemp et al., 1988; Monaghan et al., 1989 ). Figure 3 shows that 100 PM 7-Cl-Kyn completely blocked the NMDA-(300 PM) evoked release of ACh in magnesium-free medium. The partial attenuation of the light response is due to the Kyn-like activity of 7-Cl-Kyn. Co-perfusion with excess glycine reversed the NMDA antagonism due to 7-Cl-Kyn so that the same dose of NMDA produced a 17-fold increase over the basal efflux. This indicates that 7-Cl-Kyn is a competitive antagonist at the glycine binding site of the NMDA receptor. The addition of glycine also blocked the light-evoked release of ACh, from which, recovery was slow. After removing the glytine, 7-Cl-Kyn once again blocked the NMDA-evoked release of ACh, and when all drugs were washed out, a light response and a control response to NMDA were obtained. Using this pharmacological approach, it appears that the NMDA receptors mediating ACh release possess a glycine modulatory site as in other systems (Thomson, 1989) . '-7 Biochemical and physiological studies have established that DL-AP-7 is a specific NMDA antagonist, and these results have been confirmed in the rabbit retina (Perkins et al., 1982; Olverman et al., 1984; Coleman and Miller, 1988; Massey and Miller, 1990) . To establish the optimal dose of DL-AP-7 in this system, a submaximal dose of NMDA (300 PM) was tested against an increasing staircase of concentrations (Fig. 4) . After Nonlinear least-squares analysis of data from these experiments yielded the dose-response curve in Figure 5 with an IC,, of 33 I.LM for DL-AP-7 versus 300 PM NMDA. Once the optimal dose was established, we wished to confirm that was a competitive antagonist in this system. Therefore, we tested increasing concentrations of NMDA against a fixed concentration of DL-AP-7 (200 MM). As shown in Figure  6 , caused a parallel shift in the NMDA dose-response curve of one log unit. When the concentration of NMDA was raised sufficiently, from 500 PM to 5 mM, the same maximum release of ACh was obtained in the presence of Although the data points in this figure were normalized to 1, the underlying peak : base ratios were also the same. These results indicate that is a competitive NMDA antagonist in the retina, in close agreement with previous results in the retina and other systems. The NMDA dose-response curve in is dramatically different from the analogous curve in the presence of MK-801 (see below). This suggests that the 2 antagonists operate by different mechanisms.
The goal of this study was to identify the input to the cholinergic amacrine cells, so to determine the contribution of NMDA receptors, we tested against the light-evoked release of ACh. Figure 7 illustrates a self-contained experiment that may be functionally divided into 2 parts. The first half shows that had no antagonistic effect on the light response. Conversely, the light-evoked release of ACh was slightly enhanced by 14.2 & 9.3% (mean f SEM; n = 8). The significance of this small increase is unknown. The second half of this experiment is a demonstration of the pharmacological specificity of DL-AP-7. After the light-evoked controls were completed, DL-AP-7 was tested against equivalent submaximal doses of glutamate agonists. In the presence of 200 PM DL-AP-7, KA (15 I.LM) caused a 17-fold increase in the release of ACh, and QQ (15 MM), a 20-fold increase. In contrast, the response to 300 PM NMDA was abolished. After the washout of DL-AP-7, the NMDA response was comparable to those evoked by KA or QQ controls. These results demonstrate, in the same experiment, that is a specific NMDA antagonist that does not block the light-evoked release of ACh.
MK-801
The tricyclic compound MK-801 is not structurally related to glutamate, and it belongs to a different class of NMDA antagonist than DL-AP-7.
MK-801 is thought to bind to a site within the open channel of the NMDA-receptor complex instead of interacting directly with the glutamate receptor like DL-AP-7 (Wong et al., 1986) . To identify the optimal dose for MK-801, a submaximal dose of NMDA (300 PM) was tested against an After 2 light responses (asterisks), a control response to NMDA was obtained (peak : base ratio, 18.5). Perfusion with 7-Cl-Kyn partly reduced the light-evoked release of ACh but eliminated the NMDA response. Co-perfusion with glycine blocked the lightevoked release of ACh, as previously reported, but now, in the presence of 7-Cl-Kyn, NMDA caused a 17-fold increase in release. After washing out the glycine, NMDA was blocked once more by 7-Cl-Kyn. On return to control medium, light stimulation produced a normal response, and NMDA caused a 1 Ofold increase over the base line. The apparent reduction of the NMDA response through the experiment is normal, due to the exponential rundown of release and the depletion of a finite pool of labeled ACh. These results suggest that 7-Cl-Kyn is an antagonist at the allosteric glycine site of the NMDA receptor complex. Thus, MK-801 is easily the most potent antagonist we have tested in the rabbit retina.
After establishing an optimal dose of MK-801, we perfused with increasing concentrations of NMDA to see if the blockade could be overcome. However, as seen in Figure 6 , in the presence of 50 nM MK-80 1, even concentrations of NMDA as high as 10 mM failed to elicit ACh release. Thus, the NMDA dose- response curve is flat in the presence of MK-80 1. This is clearly different from DL-AP-7, and it is typical of noncompetitive antagonism. Figure 9 illustrates some other characteristics of MK-80 1 besides its high potency. After 2 light-evoked responses, perfusion with 300 PM NMDA elicited a large control response, as expected. After 12 min of perfusion with MK-801, the response to NMDA was reduced but still substantial, 8.6x the resting release rate. However, the effect of a second and subsequent applications of NMDA were abolished. In other words, the onset of MK-801 is slow, in contrast to the competitive antagonist effect on lightevoked release of ACh and pharmacological specificity. In the first half of this experiment, (200 PM; indicated by the solid bar and dotted lines) did not block the light-evoked release of ACh. Asterisks indicate light stimulation for 4 min at 3 Hz. The second half of this experiment is a demonstration of the pharmacological specificity ofm-AP-7. Perfusion with DL-AP-7 had no effect on the response to a submaximaldoseofKA(l5rM)orQQ(l5r~; peak : base ratios, 17 and 20, respectively). In contrast, the NMDA-evoked release of ACh was abolished by DL-AP-7. On return to control medium, similar responses were obtained for NMDA, QQ, and IL4 (peak: base ratios: 16, 19, and 16, respectively). As usual, control peaks at the end of the experiment are small due to the exponential decline in release, but the peak : base ratios are approximately constant. These results show, in a self-contained experiment, that is a specific NMDA antagonist that does not block the light-evoked release of ACh.
DL-AP-7, which was almost immediately effective. This observation is consistent with the idea that MK-801 is a use-dependent, open-channel blocker (Wong et al., 1986) .
Once an effective block of NMDA responses was established, we tested MK-80 1 against the light-evoked release of ACh. The effects of MK-801 on the light-evoked response were not significant (-2.35 f 7.72%, mean f SEM; n = 8). After the light responses, we wished to demonstrate the pharmacological specificity of MK-801, so equivalent doses of KA and QQ were applied. In the presence of MK-801, KA and QQ still caused massive ACh release, 27 x and 29 x the basal efflux, respectively. These results show, in the same experiment, that MK-80 1 is a specific NMDA antagonist in the rabbit retina that has no effect on the light-evoked release of ACh.
Finally, because MK-80 1 is reported to bind within the open NMDA channel in an irreversible manner, we examined the recovery of NMDA responses after the washout of MK-80 1. In the last part of Figure 9 , the NMDA block was almost total 30 min after returning to control medium. After 60 min, the NMDAevoked release of ACh was only 5 x the basal efflux, approximately 25% of the predrug control and subsequent applications of KA and QQ that produced peaks of 20 x the resting release. The long-lasting effects of MK-80 1 prevented us from obtaining postdrug controls, but this slowly irreversible action is clearly different from and typical of noncompetitive antagonists.
The , and then, a submaximal dose of NMDA (300 NM) caused a 22-fold increase over the base release. Perfusion with 50 nM MK-80 1, indicated by the solid bar and dotted lines, reduced the next NMDA response to 8 x the base release, and the following pulse of NMDA caused no release. This is consistent with a usedependent block by MK-80 1. MK-80 1 had no effect on the light-evoked release of ACh (asterisks) even after the NMDA block was established. To test the pharmacological specificity of MK-80 1, we also applied submaximal doses of other glutamate agonists, but the KA-(15 NM) and QQ-( 15 PM) evoked release of ACh was unchanged (peak: base ratios, 27 and 29, respectively). Sixty minutes after the washout of MK-80 1, the NMDA response was still blocked, but the responses to light were normal, and KA and QQ produced a 20-fold increase in release. The rundown in the gross size of responses through the experiment is normal, but the peak: base ratios are approximately the same. This experiment shows that MK-801 is a long-lasting, pharmacologically specific NMDA antagonist that does not block the lightevoked release of ACh. After 60 mitt, a pulse of NMDA was required before subsequent responses to NMDA were blocked. This is consistent with a use-dependent block by MK-80 1. The release of ACh in response to KA and QQ was not blocked by MK-801. B, Test experiment, identical to the control except for 2 periods of light stimulation (10 min, 3 Hz; double asterisks), which produced broad peaks during perfusion with MK-801. The next application of NMDA still produced a partial response, almost identical to the control, indicating that light stimulation, which effectively released ACh, did not potentiate the use-dependent block of NMDA by MK-801. Subsequent pulses of NMDA caused no release once a use-dependent block was established by the test pulse of NMDA. This result implies that the endogenous transmitter fails to open NMDA channels, so that access to MK-801 is prevented.
a self-contained experiment to test this question because the effects of MK-801 were practically irreversible. Therefore, it was necessary to conduct a separate control experiment, shown in Figure 1OA . After 2 light peaks, a control response to NMDA was obtained (peak : base ratio, 25) and then, the perfusate was switched to MK-801 (30 nM) for the rest of the experiment. After 60 min, another pulse of NMDA produced a 6-fold increase over the base release, and subsequently, the NMDA evoked release of ACh was abolished. This is typical of the slowonset, use-dependent block previously described for MK-80 1. The final responses to KA and QQ were not affected by MK-801, showing that the preparation was still functional. The test experiment in Figure 10B was identical to the control, except for light stimulation at 3 Hz for 2 periods of 10 min during perfusion with MK-80 1. However, these 3600 light flashes did not potentiate the action of MK-80 1. The following pulse of NMDA produced a 7-fold increase over the basal efflux, as in the control experiment, and then, subsequent responses to NMDA were abolished. This result implies that the endogenous transmitter did not open NMDA channels to allow the access of MK-80 1, and therefore, light stimulation did not produce a use-dependent block of NMDA responses. This is consistent with our previous observations, which suggest that the physiological input to cholinergic amacrine cells is not mediated by NMDA receptors.
Discussion
We have examined the effect of NMDA and NMDA antagonists on the release of ACh from the rabbit retina. Our results lead to 4 major conclusions: (1) NMDA causes massive ACh release in magnesium-free medium. (2) The NMDA receptors mediating ACh release possess a glycine binding site that appears to be saturated under normal conditions. (3) is a competitive NMDA antagonist, and MK-801 is a noncompetitive NMDA antagonist in the retina. (4) Four types of NMDA antagonist (Mg2+, 7-Cl-Kyn,  and MK-801) failed to block the light-evoked release of ACh. Therefore, we have been unable to demonstrate that the receptors mediating the NMDA-evoked release of ACh are activated by physiological stimulation.
NMDA
In magnesium-free medium, the glutamate agonist NMDA caused massive ACh release from the rabbit retina. The cholinergic amacrine cells are undoubtedly the source of this release because they are the only cells in the retina to synthesize ACh (Masland and Mills, 1979) . In addition, NMDA had no effect on horizontal ceils in the rabbit retina (Massey and Miller, 1987) , and pure NMDA antagonists such as DL-AP-7 did not reduce the b-wave of the electroretinogram, an indicator of bipolar cell function (Coleman and Miller, 1988; Massey and Miller, 1990) . Together, these results suggest that the receptors mediating the NMDA-evoked release of ACh are in the inner retina. The release of ACh by NMDA has been described in other systems, most notably from striatal slices Scatton and Lehmann, 1982) and this system has frequently been used to evaluate new NMDA antagonists (e.g., Lehmann et al., 1988) . However, the NMDA-evoked release of ACh from the retina is different in several ways. Striatal ACh release seems to be mediated exclusively by NMDA receptors, but in the retina, other glutamate agonists are more potent than NMDA (Linn et al., 1991) . Furthermore, the NMDA-evoked release of ACh from striatal slices was only 3-fold, but in the retina, peaks up to 50 times the resting release were obtained in response to NMDA. We do not know why the release from the retina is so large, but it may be related to the high coverage of choline& amacrine cells and the resulting density of cholinergic terminals Masland, 1984, 1985) . Alternatively, ACh release from the retina may be stronger because the tissue is intact, whereas the cells in a striatal slice have had at least some of their processes cut. It may be of general interest that ACh release from the retina is such a sensitive measure of glutamate receptor activation.
Magnesium dependence
The NMDA-evoked release of ACh from the rabbit retina was completely blocked by physiological levels of magnesium (1.2 mM), as previously reported by Cunningham and Neal (1985) . The IC,, for magnesium was 15 1 PM, which is in close agreement with earlier results (Ault et al., 1980; Lehmann and Scatton, 1982) . Therefore, even if the free magnesium concentration is partly reduced by protein binding (Foldes, 1981) , there is still enough magnesium to block the response to NMDA. In contrast, the light-evoked release of ACh and the response to other glutamate agonists were not changed by magnesium, and this suggests that NMDA receptors do not carry the physiological input to cholinergic amacrine cells.
Ganglion cells in the rabbit retina are directly excited by NMDA (Bloomfield and Dowling, 1985; Massey and Miller, 1990) , but in contrast to the release of ACh, this effect of NMDA is not magnesium dependent. This is puzzling because the ganglion cell dendrites and the cholinergic processes are intermingled in the inner plexiform layer, so they are probably exposed to the same concentration of exogenous NMDA or magnesium. We cannot explain this difference, but we note that there is preliminary evidence for multiple NMDA receptor subtypes (Young and Fagg, 1990 ).
Requirement for glycine
The NMDA-evoked release of ACh from the rabbit retina was not potentiated by additional glycine or reduced in glycine-free medium. However, 7-Cl-Kyn, an antagonist at the glycine site ofthe NMDA receptor (Kemp et al., 1988) , blocked the response to NMDA. Furthermore, the action of 7-Cl-Kyn was reversed by exogenous glycine (Fig. 3) . This indicates that 7-Cl-Kyn and glycine compete for the same site in the retina and demonstrates the presence of an allosteric glycine binding site. Glycine was also shown to potentiate the response to NMDA in ganglion cells under culture conditions where the level of glycine is low (Fain et al., 1989) . From these results, we deduce that the glycine binding site is normally saturated by endogenous glycine.
Antagonists
The major goal of this study was to determine the contribution of NMDA receptors to the light-evoked release of ACh. We chose to use DL-AP-5 as an NMDA antagonist because the homologue has some activity at the 2-amino-4-phosphonobutyrate (APB) receptor (Slaughter and Miller, 1985; Coleman and Miller, 1988; Massey and Miller, 1990) . Our results show that is a specific and competitive NMDA antagonist (IC,,, 33 MM), in agreement with previous work in the retina and other systems (Olverman et al., 1984; Massey and Miller, 1990) . In contrast to Cunningham and Neal (1985) , we found no evidence that NMDA antagonists could block the KA-evoked release of ACh.
MK-801 (IC,,, 10.6 nM) was a pharmacologically selective NMDA antagonist over 3 log units more potent than DL-AP-7. In addition, the blockade of NMDA responses by MK-80 1 was slow in onset, irreversible, and could not be overcome by excess NMDA. These observations are consistent with previous work indicating that MK-80 1 is a noncompetitive, use-dependent NMDA antagonist (Wong et al., 1986; Karschin et al., 1988) .
Once the dose and specificity were established, we tested these antagonists against the light-evoked release of ACh. However, even in magnesium-free medium, neither antagonist reduced the light response, though in the same experiments, the NMDAevoked release of ACh was abolished. It is convincing that we obtained the same result with 2 antagonists that act at different sites, at the NMDA receptor and MK-80 1 at the open channel. Furthermore, 7-Cl-Kyn, which is an antagonist at the glycine site, and magnesium did not block the light-evoked release of ACh. These observations indicate that NMDA receptors do not mediate the light-evoked release of ACh from the rabbit retina. This result is complementary to our previous work with the KA antagonist DNQX, which blocked the light-evoked release of ACh but not the NMDA response (Linn et al., 1991) . This indicates that KA receptors, and not NMDA receptors, mediate the physiological input to the cholinergic amacrine cells. One of the counterintuitive properties of MK-80 1 is that the blockade is dependent on the presence of NMDA. This usedependent block, which we have observed in the retina (Fig. 9) , suggests that MK-80 1 interacts with the open state ofthe NMDAassociated channel (Wong et al., 1986) . However, prolonged light stimulation was not sufficient to activate the use-dependent block of NMDA responses by MK-80 1 (Fig. 10) . From this, we deduce that light stimulation, though it causes ACh release, does not activate NMDA receptors in this pathway. In other words, the endogenous transmitter does not open the NMDA channel to permit the access of MK-801. Again, this indicates that the input to the cholinergic amacrine cells is not mediated by NMDA receptors.
Function of NMDA receptors
From the results described above, we are confident that NMDA receptors do not mediate the light-evoked release of ACh under our experimental conditions. However, we were constrained to use a diffuse light as a stimulus. Is it possible that a spatially optimal stimulus could generate a response mediated by NMDA receptors? The obvious case is the response to a moving stimulus because directionally selective ganglion cells in the rabbit retina are well known to receive input from cholinergic amacrine cells (Masland and Ames, 1976; Ariel and Daw, 1982) , and NMDA receptors could be well suited for this kind of nonlinear response.
We think this is unlikely because a drifting grating produced the same amount of ACh release as diffuse stimulation (O'Malley and Masland, 1989) . In addition, directional selectivity in ganglion cells is not blocked by NMDA antagonists (Massey and Miller, 1990) . Instead, the mechanism of directional selectivity appears to be dependent on asymmetrical GABA inhibition (Wyatt and Daw, 1976; Daw et al., 1989) .
Ganglion cells in the rabbit retina receive part of their input via NMDA receptors, and a slow NMDA component has been reported in the salamander retina (Mittman and Taylor, 1988; Massey and Miller, 1990) . Thus, ganglion cells appear to have dual postsynaptic glutamate receptors, as reported in other systems. In addition, there are many functions for NMDA receptors besides fast synaptic transmission. NMDA receptors may be important for slow modulation, calcium regulation, and the control of plasticity, among other possibilities. At this time, our understanding of the physiological significance of NMDA receptors appears to lag behind our knowledge of the receptor and its pharmacology (Dale, 1989) .
